CA2033447A1 - Complexe synergique pour le traitement des infections herpetiques - Google Patents

Complexe synergique pour le traitement des infections herpetiques

Info

Publication number
CA2033447A1
CA2033447A1 CA2033447A CA2033447A CA2033447A1 CA 2033447 A1 CA2033447 A1 CA 2033447A1 CA 2033447 A CA2033447 A CA 2033447A CA 2033447 A CA2033447 A CA 2033447A CA 2033447 A1 CA2033447 A1 CA 2033447A1
Authority
CA
Canada
Prior art keywords
treating herpes
herpes infections
synergistic combination
combination
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2033447A
Other languages
English (en)
Other versions
CA2033447C (fr
Inventor
Robert Deziel
Yvan Guindon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Canada Ltd
Original Assignee
Bio Mega Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Mega Inc filed Critical Bio Mega Inc
Priority to CA002033447A priority Critical patent/CA2033447C/fr
Priority to US07/809,611 priority patent/US5380727A/en
Priority to NZ241120A priority patent/NZ241120A/en
Priority to DE69125262T priority patent/DE69125262T2/de
Priority to EP91122059A priority patent/EP0493767B1/fr
Priority to AT91122059T priority patent/ATE150317T1/de
Priority to JP34421891A priority patent/JP3209553B2/ja
Priority to IL10055091A priority patent/IL100550A/en
Priority to AU90091/91A priority patent/AU648854B2/en
Publication of CA2033447A1 publication Critical patent/CA2033447A1/fr
Application granted granted Critical
Publication of CA2033447C publication Critical patent/CA2033447C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un dispositif de spectroscopie Raman exaltée de surface comprend un substrat non électroconducteur, des microélectrodes disposées sur le substrat dans une relation espacée de sorte qu'un site de détection est formé le long des bords et/ou entre des bords opposés des microélectrodes, et une structure de nanoparticules comprenant une pluralité de nanoparticules métalliques disposées dans le site de détection. L'assemblage de la structure à nanoparticules peut être dirigé par un champ électrique entre les micro-électrodes. Le dispositif de spectroscopie Raman exaltée de surface est robuste, portable, réutilisable et peu coûteux. Il est également décrit des procédés d'utilisation et de préparation des dispositifs de spectroscopie Raman exaltée de surface à l'aide de techniques de fabrication simples, rapides et peu coûteuses.
CA002033447A 1990-12-31 1990-12-31 Complexe synergique pour le traitement des infections herpetiques Expired - Fee Related CA2033447C (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002033447A CA2033447C (fr) 1990-12-31 1990-12-31 Complexe synergique pour le traitement des infections herpetiques
US07/809,611 US5380727A (en) 1990-12-31 1991-12-17 Synergistic combination for treating herpes infections
NZ241120A NZ241120A (en) 1990-12-31 1991-12-20 Antiviral composition for treating herpes comprising a nucleoside analog
EP91122059A EP0493767B1 (fr) 1990-12-31 1991-12-21 Combinaison synergique pour le traitement de l'herpès
DE69125262T DE69125262T2 (de) 1990-12-31 1991-12-21 Synergische Mischung zur Behandlung von Herpes
AT91122059T ATE150317T1 (de) 1990-12-31 1991-12-21 Synergische mischung zur behandlung von herpes
JP34421891A JP3209553B2 (ja) 1990-12-31 1991-12-26 ヘルペス感染治療用医薬組成物
IL10055091A IL100550A (en) 1990-12-31 1991-12-30 Anti-herpes pharmaceuticals and cosmetics containing a combination of an antiviral nucleic acid analogue and the history of a reductase inhibitory ribomocalotide peptide
AU90091/91A AU648854B2 (en) 1990-12-31 1991-12-30 Synergistic combination for treating herpes infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002033447A CA2033447C (fr) 1990-12-31 1990-12-31 Complexe synergique pour le traitement des infections herpetiques

Publications (2)

Publication Number Publication Date
CA2033447A1 true CA2033447A1 (fr) 1992-07-01
CA2033447C CA2033447C (fr) 1999-08-31

Family

ID=4146736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002033447A Expired - Fee Related CA2033447C (fr) 1990-12-31 1990-12-31 Complexe synergique pour le traitement des infections herpetiques

Country Status (9)

Country Link
US (1) US5380727A (fr)
EP (1) EP0493767B1 (fr)
JP (1) JP3209553B2 (fr)
AT (1) ATE150317T1 (fr)
AU (1) AU648854B2 (fr)
CA (1) CA2033447C (fr)
DE (1) DE69125262T2 (fr)
IL (1) IL100550A (fr)
NZ (1) NZ241120A (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0560267B1 (fr) * 1992-03-12 1998-08-19 Boehringer Ingelheim (Canada) Ltd. Dérivés peptidiques isostères contre l'herpès
JP4110347B2 (ja) * 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
WO2001057072A2 (fr) 2000-02-07 2001-08-09 Wisconsin Alumni Research Foundation Peptides antiviraux pharmacologiquement actifs et leurs methodes d'utilisation
US7432045B2 (en) * 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2013312296B2 (en) 2012-09-10 2017-06-22 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EA033900B1 (ru) 2014-02-21 2019-12-06 Принсипиа Биофарма Инк. СОЛЕВЫЕ И АМОРФНЫЕ ФОРМЫ 2-[(3R)-3-[4-АМИНО-3-(2-ФТОР-4-ФЕНОКСИФЕНИЛ)ПИРАЗОЛО[3,4-d]ПИРИМИДИН-1-ИЛ]ПИПЕРИДИН-1-КАРБОНИЛ]-4-МЕТИЛ-4-[4-(ОКСЕТАН-3-ИЛ)ПИПЕРАЗИН-1-ИЛ]ПЕНТ-2-ЕННИТРИЛА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ПУЗЫРЧАТКИ ОБЫКНОВЕННОЙ И ПУЗЫРЧАТКИ ЛИСТОВИДНОЙ С ИХ ПРИМЕНЕНИЕМ
EA036269B1 (ru) 2014-12-18 2020-10-21 Принсипиа Биофарма Инк. Лечение пузырчатки
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
US20190231784A1 (en) 2016-06-29 2019-08-01 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP6510578B2 (ja) 2017-03-28 2019-05-08 本田技研工業株式会社 ヘッドアップディスプレイ装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
GB8815241D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Antiviral combinations & compounds therefor

Also Published As

Publication number Publication date
JP3209553B2 (ja) 2001-09-17
DE69125262T2 (de) 1997-10-09
NZ241120A (en) 1994-02-25
ATE150317T1 (de) 1997-04-15
JPH04275230A (ja) 1992-09-30
DE69125262D1 (de) 1997-04-24
EP0493767B1 (fr) 1997-03-19
EP0493767A3 (en) 1993-03-17
US5380727A (en) 1995-01-10
EP0493767A2 (fr) 1992-07-08
AU9009191A (en) 1992-07-02
AU648854B2 (en) 1994-05-05
IL100550A0 (en) 1992-09-06
CA2033447C (fr) 1999-08-31
IL100550A (en) 1995-11-27

Similar Documents

Publication Publication Date Title
CA2033447A1 (fr) Complexe synergique pour le traitement des infections herpetiques
GR3034917T3 (en) Bis-Staurosporine and K-252a derivatives
AU2219792A (en) Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
AU7334194A (en) Characteristic of body part determined
NZ241121A (en) Antiviral composition for treating herpes comprising a nucleoside analog & a ribonucleotide reductase inhibiting peptide derivative
AU5254696A (en) Reduced toxicity compositions and methods for treating hiv infections
AU557894B2 (en) Interferon-guanine synergistic anti-herpes composition
AU4746493A (en) Belt fastening arrangement
PL309610A1 (en) Purine derivatives
AU661379B2 (en) Method of reducing or preventing toxicity associated with antiretroviral therapy
AU9079491A (en) Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
AU5883794A (en) Diazepin derivatives and antiviral compositions
AU2448292A (en) Pyrimidine derivative and weedkiller
AU2591692A (en) Method of treating latent herpes viral infections
EP0453247A3 (fr) Composés antivirals
AU4257896A (en) Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpes virus infections
AU7389794A (en) Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
AU3298193A (en) Derivatives of saturated nitrogen heterocycles
AU4167293A (en) Heterocyclyl-phenoxyalkyl-piperidinylpyridazines as antiviral agents
AU3512793A (en) Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
ZA948908B (en) Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 7 infection
AU3395993A (en) Process for the expression of herpes simplex virus type 1 glycoprotein E and methods of use
ZA948907B (en) Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 6 infections
AU5554594A (en) Antiviral agents
AU9073691A (en) Combinations of vanilloid compounds and nucleoside antiviral compounds for treatment of herpes infections

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20031231